4172.Two
4172.TWO is a pharmaceutical company that operates in the healthcare sector, primarily engaged in the development and commercialization of pharmaceutical products.
Business. 4172.TWO is a pharmaceutical company that operates in the healthcare sector, primarily engaged in the development and commercialization of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4172.TWO is a pharmaceutical company that operates in the healthcare sector, primarily engaged in the development and commercialization of pharmaceutical products.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative approach to financing, with a strong equity base of 419,176,000 TWD and total liabilities of 49,805,000 TWD. The liquidity position is robust, as evidenced by a current ratio of 3.52 and a substantial cash and equivalents balance of 97,280,000 TWD. However, the company's operating cash flow is negative at -134,192,000 TWD, and free cash flow is also negative at -178,349,000 TWD, suggesting significant cash outflows from operations.
Profitability metrics are concerning, with a return on equity of -0.4399 and a return on assets of -0.3932, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -171,837,000 TWD, and the net income is also negative at -184,398,000 TWD, reflecting a challenging financial performance. These figures are below the industry median for profitability metrics, suggesting that the company is underperforming relative to its peers.
The company's revenue is concentrated in a single segment, with no disclosed geographic diversification. The revenue concentration is not specified, but the lack of segment and geographic data suggests a potential risk of over-reliance on a single market or product line. The company's growth trajectory is also concerning, with a negative operating income and net income, indicating a decline in profitability. The company's revenue of 68,987,000 TWD is a key metric to monitor for future performance.
Risk factors include a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's capital expenditure is minimal at -276,000 TWD, suggesting a conservative approach to reinvestment. The company's shares outstanding are the same for both basic and diluted shares, indicating no significant dilution potential.
Recent events include the last actual EPS of -2.87 TWD and the last actual revenue of 33,791,000 TWD, as reported by analysts. These figures highlight the company's ongoing financial challenges and the need for strategic improvements to enhance profitability and cash flow generation.
- The company has a strong equity base and low debt, but is experiencing significant cash outflows from operations.
- Profitability metrics are negative, indicating poor performance relative to industry standards.
- The company's revenue is concentrated in a single segment, with no geographic diversification disclosed.
- Growth is constrained by negative operating and net income figures.
- Liquidity and dilution risks are low, but the company needs to address its cash flow and profitability issues.
- **margin_outlook_rationale**: The company's negative operating and net income suggest a deteriorating margin outlook driven by high operating costs and low revenue.
- **rd_outlook_rationale**: No specific R&D outlook is provided, but the company's negative cash flow may limit investment in research and development.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4172.TWO Market data — financials · 2026-05-26
- Innopharmax Inc Market data — analyst estimates · 2026-05-26